Halt of Polyphor trial shrinks company val...Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080). more ➔
Ethics Council calls for moratorium of cli...Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention. more ➔
BioNtech aquires antibody assets from MabV...Immunotherapy and infection specialist BioNTech SE (Mainz, Germany) has acquired preclinical and clinial antibody assets and infrastructior from MabVax Therapeutics Holding, Inc. more ➔
MS linked to epigenetic changes in immune...Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment. more ➔
Confo Therapeutics raise €30m in Series...The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributi … more ➔
Researchers report how body fat affects im...US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33). more ➔
European Lead Factory gets €36.5m suppor... The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative. more ➔
AstraZeneca set to licence 5 programmes fr...Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgènes armed oncolytic immunotherapies. more ➔
Alentis Therapeutics debuts with CHF12.5m Liver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures. more ➔
EMA recommends nine drugs for market appro... In its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation. more ➔